

Changes to the Michigan Pharmaceutical Product List and the Preferred Drug List Effective January 15, 2009

Following the December 2, 2008 meeting of the Michigan Pharmacy and Therapeutics Committee, the Department will make the following changes to pharmaceutical coverage in the programs managed by the Department:

Cimzia; will be added to the Michigan Pharmaceutical Product List (MPPL), and to the Preferred Drug List (PDL) class, “Biologic immunomodulators” without prior authorization (PA); no health care professional services for administration outside the office or clinic setting will be reimbursed

Relistor: will be added to the MPPL without PA

Durezol Ophthalmic: will be added to the MPPL without PA

Actonel 150mg: will be added to the MPPL and to the PDL with PA

Aldex AN: will be added to the MPPL with strict PA criteria

Liquadd: will be added to the MPPL with strict PA criteria

Requip XL: will be added to the MPPL and to the PDL class “Non Ergot Dopamine Receptor Agonists” without PA

Evamist: will be added to the MPPL with strict PA criteria

Millipred; will be added to the MPPL with strict PA criteria

Taclonex scalp susp: will be added to the MPPL with strict PA criteria

Papfyll foam: will be added to the MPPL with PA

Doryx: will be added to the MPPL with age edits applicable to tetracyclines

Xolegel: will be added to the MPPL with strict PA criteria

Celebrex will no longer require PA, but with quantity limits per prescription

Vyvanse will no longer require PA, but with quantity limits per prescription and with the clinical edits applied to all ADHD drugs

Rozerem will be available without PA, but will have an edit to require prior authorization if beneficiary has had paid claims for benzodiazepine or other sedative hypnotics within the past six months before the prescription for Rozerem